$65.00
-1.53[-2.30%]
At close: May 17
$65.00
0[0.00%]
After Hours: 4:00PM EDT
Intra-Cellular Therapies
(NASDAQ:ITCI)Intra-Cellular Therapies Stock (NASDAQ:ITCI), Analyst Ratings, Price Targets, Predictions
Intra-Cellular Therapies Inc has a consensus price target of $84.88, established from looking at the 73 latest analyst ratings. The last 3 analyst ratings were released from Needham, Needham, and Cantor Fitzgerald on May 8, 2024, May 7, 2024, and April 24, 2024. With an average price target of $100 between Needham, Needham, and Cantor Fitzgerald, there's an implied 53.85% upside for Intra-Cellular Therapies Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
Cantor Fitzgerald
Canaccord Genuity
Mizuho
Goldman Sachs
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Intra-Cellular Therapies
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2024 | Buy Now | 38.46% | Needham | Ami Fadia | → $90 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 38.46% | Needham | Ami Fadia | → $90 | Reiterates | → Buy | Get Alert |
| 04/24/2024 | Buy Now | 84.62% | Cantor Fitzgerald | Charles Duncan | → $120 | Reiterates | Overweight → Overweight | Get Alert |
| 04/23/2024 | Buy Now | 64.62% | Canaccord Genuity | Sumant Kulkarni | $100 → $107 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | 38.46% | Needham | Ami Fadia | $82 → $90 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | 47.69% | Mizuho | Graig Suvannavejh | $82 → $96 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 18.46% | Goldman Sachs | Corinne Jenkins | $67 → $77 | Maintains | Neutral | Get Alert |
| 04/17/2024 | Buy Now | 40% | B of A Securities | Jason Gerberry | $82 → $91 | Maintains | Buy | Get Alert |
| 04/17/2024 | Buy Now | 58.46% | Baird | Joel Beatty | $83 → $103 | Maintains | Outperform | Get Alert |
| 04/17/2024 | Buy Now | 38.46% | TD Cowen | Joseph Thome | $80 → $90 | Maintains | Buy | Get Alert |
| 04/16/2024 | Buy Now | 26.15% | Needham | Ami Fadia | → $82 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | Buy Now | 26.15% | Needham | Ami Fadia | → $82 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | Buy Now | 32.31% | RBC Capital | Brian Abrahams | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 02/23/2024 | Buy Now | 55.38% | Cantor Fitzgerald | Charles Duncan | → $101 | Reiterates | Overweight → Overweight | Get Alert |
| 02/23/2024 | Buy Now | 32.31% | RBC Capital | Brian Abrahams | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 02/23/2024 | Buy Now | 53.85% | Canaccord Genuity | Sumant Kulkarni | $101 → $100 | Maintains | Buy | Get Alert |
| 02/23/2024 | Buy Now | 26.15% | Needham | Ami Fadia | $72 → $82 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 26.15% | Mizuho | Graig Suvannavejh | $76 → $82 | Maintains | Buy | Get Alert |
| 01/31/2024 | Buy Now | 32.31% | RBC Capital | Brian Abrahams | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 01/18/2024 | Buy Now | -1.54% | Goldman Sachs | Corinne Jenkins | $58 → $64 | Maintains | Neutral | Get Alert |
| 01/03/2024 | Buy Now | 27.69% | Baird | Joel Beatty | → $83 | Initiates | → Outperform | Get Alert |
| 01/02/2024 | Buy Now | 26.15% | B of A Securities | Ashwani Verma | $74 → $82 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | 55.38% | Cantor Fitzgerald | Charles Duncan | → $101 | Reiterates | Overweight → Overweight | Get Alert |
| 12/11/2023 | Buy Now | 15.38% | TD Cowen | Joseph Thome | → $75 | Initiates | → Outperform | Get Alert |
| 11/03/2023 | Buy Now | 16.92% | RBC Capital | Brian Abrahams | $77 → $76 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | 55.38% | Cantor Fitzgerald | Charles Duncan | $98 → $101 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | 10.77% | Needham | Ami Fadia | $71 → $72 | Maintains | Buy | Get Alert |
| 08/22/2023 | Buy Now | 50.77% | Cantor Fitzgerald | Charles Duncan | → $98 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | 23.08% | Morgan Stanley | Jeffrey Hung | $80 → $80 | Reiterates | Overweight → Overweight | Get Alert |
| 08/04/2023 | Buy Now | 21.54% | RBC Capital | Brian Abrahams | $78 → $79 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Intra-Cellular Therapies (ITCI)?
The latest price target for Intra-Cellular Therapies (NASDAQ: ITCI) was reported by Needham on May 8, 2024. The analyst firm set a price target for $90.00 expecting ITCI to rise to within 12 months (a possible 38.46% upside). 37 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Intra-Cellular Therapies (ITCI)?
The latest analyst rating for Intra-Cellular Therapies (NASDAQ: ITCI) was provided by Needham, and Intra-Cellular Therapies reiterated their buy rating.
When was the last upgrade for Intra-Cellular Therapies (ITCI)?
There is no last upgrade for Intra-Cellular Therapies.
When was the last downgrade for Intra-Cellular Therapies (ITCI)?
The last downgrade for Intra-Cellular Therapies Inc happened on August 22, 2022 when Goldman Sachs changed their price target from $64 to $49 for Intra-Cellular Therapies Inc.
When is the next analyst rating going to be posted or updated for Intra-Cellular Therapies (ITCI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intra-Cellular Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intra-Cellular Therapies was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.
Is the Analyst Rating Intra-Cellular Therapies (ITCI) correct?
While ratings are subjective and will change, the latest Intra-Cellular Therapies (ITCI) rating was a reiterated with a price target of $0.00 to $90.00. The current price Intra-Cellular Therapies (ITCI) is trading at is $65.00, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.